Provided by Tiger Trade Technology Pte. Ltd.

Capital Research Global Investors

2,944.66
+17.100.58%
Number of Gainers:61
Number of Losers:34
Number of Flat:- -
PE:- -
High:2,948.15
Open:2,927.54
Low:2,924.30
Close:2,927.54
Volume:391.27M
Turnover:61.65B
Market Cap:33.66T
Float Cap:31.99T

Loading ...

General Mills Inc. Stock Sheds 4.9%, Underperforms Peers

Dow Jones
·
Oct 01

Cboe Global Markets Inc. Stock Climbs 5.2%, Outperforms Peers

Dow Jones
·
Oct 01

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Oct 01

Google Launches Gemini 4 Argon, Sets New Software Engineering Record

TIPRANKS
·
Oct 01

Top News Today/Canada: TD Bank Plans to Repurchase up to C$10 Billion of Stock

Dow Jones
·
Oct 01

Press Release: TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness

Dow Jones
·
Oct 01

Micron Q4 Revenue Surpasses $54.2 Billion in a Single Quarter, Forecasts Persistent Memory Supply Shortage Through 2027-2028

Deep News
·
Oct 01

Broadcom Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Alphabet Inc. Cl C Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 01

Airbnb Chief Strategy Officer Nathan Blecharczyk Disposes of USD 2,122,288 in Class a Shares

Reuters
·
Oct 01

Micron sees memory, storage supply-demand conditions much tighter in FY27, FY28

TIPRANKS
·
Oct 01

Micron says next-gen DRAM, NAND nodes on track for volume production in 2H27

TIPRANKS
·
Oct 01

Micron sees server unit growth in high-teens percentage in 2026, 2027

TIPRANKS
·
Oct 01

BCE Inc. Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Oct 01

Micron Delivers Q4 Double Beat, Sees 'Even Stronger' Year Ahead

Benzinga Earnings
·
Oct 01

Biomarin Pharmaceutical - Co and Ascendis to Dismiss All Pending Litigation with Prejudice - SEC Filing

THOMSON REUTERS
·
Oct 01

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% US, 18% EU/Br/SK Royalty on Sales Until May 2030 - SEC Filing

THOMSON REUTERS
·
Oct 01

Biomarin Pharmaceutical - Grants Ascendis License for Transcon Cnp, Navepegritide, Yuviwel - SEC Filing

THOMSON REUTERS
·
Oct 01

Micron Technology Inc: Project Capex to be Higher in Second Half of Fiscal 2027

THOMSON REUTERS
·
Oct 01

Micron Technology: Expect Memory & Storage Supply-Demand Conditions to be Much Tighter in Fiscal 2027 & 2028 than in 2026 - Prepared Remarks

THOMSON REUTERS
·
Oct 01